Thank you!
Your support is sustaining the future of local news in our communities.

Omicron, surely that’s enough

What have the scientific, pharmaceutical, and medical communities done to stifle SARS-CoV-2 infections? There are currently 18 advanced trials of different vaccines, 64 possible new treatments, and 23 potential or approved anti-viral drugs.

The mRNA vaccines from Pfizer and Moderna provide robust protection. (The mRNA technology is being expanded to HIV, malaria, and other diseases for which conventional vaccines have failed.) mRNA vaccines are expensive and need to be shipped frozen. Lower income countries require an effective vaccine that is inexpensive, survives at higher temperature and can be made locally.  Corbevax, created at Baylor College of Medicine, fits these criteria and is currently being made in hundreds of millions of doses in India. Other vaccines (Novovax) produce antibodies to viral proteins in addition to the Spike protein. The Novovax vaccine contains no genetic material.

Beyond vaccines there are 64 new treatments in development that block or slow infection or some of its consequences, like inflammation. Inflammation makes blood vessels leaky; defensive cells, which rush to the site of infection, squeeze out of the circulation, and infiltrate the lungs. They fill air sacs with dead neutrophils, eosinophils, and fluid, making the patient struggle to breathe.  In addition to the inflammatory reaction, when these cells die they release digestive enzymes that can do terrible damage to the lungs or other infected tissues. The use of steroids to inhibit inflammation was a critical early discovery. According to a review I read recently, it is still the best early intervention. Most viruses have means to inhibit a host’s immune system:  some inhibit interferon synthesis, a critical mobilizer of the immune response; SARS-CoV-2 inhibits the production of Natural Killer cells, which recognize infected lung cells and kill them. The more we know about these mechanisms the better off we will be.

There are currently 23 antivirals approved or in testing, including Merck’s Molnupiravir and Pfizer’s Paxlovid, but others have Emergency Use Authorizations as well. Paxlovid, if taken within 5 days of the onset of symptoms, blocks disease progression and keeps 90% of patients from hospitalization.  As a result, our hospitals are able to function, saving money, reducing misery and increasing morale.  Vaccinated and boosted people usually have a short illness unless they have other complications and may not need these therapeutics. But for those who do, or are unvaccinated the drugs are becoming available in pharmacies.

My friend, Jonathan Sanoff, keeps track of these things. He told me about a site called the Therapeutics Locator, which The Assistant Secretary for Preparedness and Response at The Department of Health and Human Services and her staff have prepared. The Assistant Secretary is Rear Admiral Rachel L. Levine, MD. The site tells potential patients where to find these drugs, whether they are in Puerto Rico or Alaska. For skeptics, the site also includes the number of doses on hand at each site and the total made so far, as well as information on each drug. As new therapies come online, they will appear on the Therapeutics Locator. There are currently seven drugs and monoclonal antibodies on the site. The Asst Secretary and her staff do not get much credit, but they should. See: www.covid-19-therapeutics-locator-dhhs.hub.arcgis.com/.

It is important to have many anti-viral drugs, and I was surprised to learn that 23 are still in late clinicals trials. We learned from HIV therapy that an RNA virus can develop resistance to a single drug but cannot evolve resistance to three drugs and is why the number 23 is a pleasant surprise. An even better surprise is, some of these drugs inhibit other RNA viruses, including Zika and Ebola.

Nothing in science or medicine must work, no matter how clever the idea. We should not be surprised that 26 vaccines failed, 92 treatments did not pass muster, and 54 antivirals did not inhibit SARS-CoV-2.  These results on therapies in the development pipeline have been collected by Heidi Ledford, one of Nature Magazine’s senior reporters (Nature, March 3, 2022). I am grateful to her. In that context, the March 11 issue of Science, the flagship publication of the American Academy of Sciences, contains a detailed comparison and analysis of these treatments and ideas on what we need to prepare for the next epidemic. Pandemics are too large a subject to cover everything — we have left out the value of logistics and convincing people to take vaccines, not to mention long Covid, but people are studying these challenges. The combination of basic science, private industry, and public health services have done well, although praise sounds hollow when millions have died.

What to do? Get vaccinated and boosted. When new boosters designed to attack SARS-CoV-2 or its variants appear, get those too. Even with the vaccine, you may get mild disease, but the name of the game is to prevent progress to serious disease and hospitalization. The new drugs offer reassurance. In places where the virus and infection are in decline, it is time to resume normal life.  Or at least that is my plan.

 

Richard Kessin is Emeritus Professor of Pathology and Cell Biology at the Columbia University Irving Medical Center. Reach him at Richard.Kessin@gmail.com. His website contains more information: RichardKessin.com.

 

 

       

             

 

The views expressed here are not necessarily those of The Lakeville Journal and The Journal does not support or oppose candidates for public office.

Latest News

Bed Race returns to North Canaan Saturday night, still time to register

The Royal Flush won the bed race in 2025.

John Coston

NORTH CANAAN — The Annual Bed Race will return to Summer Nights of Canaan on Saturday July 18, following the Fireman’s Parade at 6 p.m.

Now a Summer Nights tradition, and before that, a staple of Railroad days since the early 1990s — the Bed Race is back after being revived in recent years by Will and Samantha Perotti. After the event lay dormant for several years, the couple volunteered to take it over and have been working to grow participation.

Keep ReadingShow less
Grand jury indicts Cole Bushnell on murder, evidence tampering charges

Cole Bushnell appears in Berkshire Superior Court on Thursday after a grand jury indicted him on charges of murder and evidence tampering.

Madi Long

An Ashley Falls man whose arrest drew attention on both sides of the Massachusetts-Connecticut border has been indicted on charges of murder and evidence tampering in connection with the June 1 killing of Michael A. Moore, a former Falls Village resident.

A Berkshire County grand jury has indicted Cole Bushnell, 41, on charges of murder and evidence tampering in the death of Moore, 40, of Winsted. The evidence tampering count is a new felony charge, with prosecutors alleging that Bushnell attempted to destroy his cellphone following the killing to conceal evidence.

Keep ReadingShow less

Angry bees close Mudge Pond Beach

Angry bees close Mudge Pond Beach

Officials closed the Sharon town beach at Mudge Pond on Wednesday, July 15, after a fallen tree limb exposed a large beehive. The beach is expected to reopen Thursday.

Alec Linden

SHARON – The town beach on Mudge Pond closed on Wednesday, July 15, but the cause wasn’t the smoky haze drifting in from Canadian wildfires – it was angry bees.

According to Sharon’s Parks and Recreation Director Bryan Failla, a large limb fell from an old tree near the lifeguard stand overnight, exposing a hole that houses a large beehive. He said the town made the decision to close the beach Wednesday morning “out of an abundance of caution.”

Keep ReadingShow less
google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.

Millerton dressmaker forged path as early businesswoman
Mary Kisselbrack, left, and her husband, George.
Provided

If you’ve driven down Main Street in Millerton, you’ve passed the former home and shop of one of the village’s earliest female entrepreneurs. At a time when most businesses were owned by men, Mary Kisselbrack made a name for herself in the late 1800s as a well-respected milliner and dressmaker.

On April 11, 1891, train conductor George Kisselbrack purchased a 124-by-232-foot vacant lot at 54 Main St. and hired locally renowned builders Beers and Trafford to design what would become their home and Mary’s business.

Keep ReadingShow less
Wastewater project coming to fruition after decades of debate

Millerton’s business community will soon see the completion of a public wastewater system, addressing what local officials and business owners have called a major constraint on commercial development in the community for decades.

The $13.8 million project, which is expected to serve the core of the Village of Millerton and a commercial stretch of the Town of North East along U.S. Route 44, represents one of the largest infrastructure investments in the community in decades, and brings an end to calls for a sewer system that stretch back to World War II. Officials say the system will safeguard local waterways while creating a foundation for long-term economic stability.

Keep ReadingShow less
Millerton Moviehouse marks 120 years with structural upgrades

Wooden beams made from tree trunks comprise the load-bearing structure under Millerton’s Moviehouse.

Graham Corrigan

There are a handful of buildings that have stood the test of time over Millerton’s 175-year history. But if there’s one that stands out as a singular representation of the town, it’s the Millerton Moviehouse and its iconic clock tower.

Built in 1903 as a grange hall, it was soon converted into a movie theater with a second-floor ballroom. It was one of a handful of buildings that came to define the town in the following decades, standing tall across the street from the Episcopal Church and Millerton Inn, next to Terni’s, and up the hill from Millerton’s train station.

Keep ReadingShow less
google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.

google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.